DAVID GRANOVSKY

Archive for October 27th, 2011|Daily archive page

SILENCE OF THE LAMBS MEETS STEM CELLS! – THE HARDCORE SCIENCE

In ALL ARTICLES on October 27, 2011 at 8:57 pm

Tolerance to Composite Tissue Allografts is Dependent on the Administration of Hematopoietic Stem Cells but not Long-Term Engraftment

David Mathes1,2, Jeff Chang1,2, Scott Graves2, Billana Huang2, Tiffany Miwongtum2, Rainer Storb2

1Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Washington; 2Transplantation Biology Research Center, Fred Hutchinson Cancer Research Center; Seattle, Washington, USA

Introduction: Composite tissue allografts (CTA) are a clinical reality.  However, the survival of these transplants is dependent on immunosuppression. This experiment sought to develop a large animal model for the simultaneous transplantation of hematopoietic stem cells (HSC) and CTA using our mixed chimerism protocol and to examine the role of the HSC infusion.

Methods: 4 transplants were performed across a DLA matched, minor mismatch barrier. All dogs received 200 cGy of radiation and a CTA transplant with injection of HSC. 3 dogs underwent the protocol except without an HSC infusion. All dogs received 35 days of post-grafting immunosuppression and were followed for donor cell chimerism and underwent biopsies. Tolerant animals underwent a donor and third-party skin graft. Finally, they were followed for levels of FoxP3 and GranzymeB in the transplanted muscle and skin.

Results: All of the experimental animals demonstrated long-term tolerance to the CTA (497, 467, 465, and 400 days). 3 of 4 dogs had long-term detectable donor chimerism. One dog lost its chimerism at 10 weeks post-transplant but remained tolerant to the CTA. The expression of CD3+ FoxP3 was stable in the tolerant transplanted muscle and skin.  It was also noted to be elevated in the draining lymph node. The three dogs transplanted without an HSC infusion rejected their transplants at 45 days after the cessation of post-grafting immunosuppression. All of the tolerant dogs accepted the donor skin graft and promptly rejected the third-party graft.

Conclusion: The simultaneous transplant of HSC and CTA leads to tolerance. This tolerance induction appears to be dependent on the administration of HSC but not its long-term engraftment. This finding suggests that modifications to the protocol that promote initial engraftment but not long-term presence of donor cells will be key to the development of a protocol that can used on complete mismatched transplants.

http://www.bss2011.org/index.php?option=com_content&view=article&id=169:557&catid=5:poster-abstracts&Itemid=39

DAMN! SILENCE OF THE LAMBS MEETS STEM CELLS!

In VICTORIES & SUCCESS STORIES on October 27, 2011 at 8:01 pm

SILENCE OF THE LAMBS MEETS STEM CELLS and future transplant recipients win big!!

https://repairstemcell.files.wordpress.com/2011/10/anthony_hopkins_hannibal_lecter.jpg?w=147Remember in Silence of the Lambs, at the end of the movie, when Hannibal Lecter cuts off the guards face and then wears it out to escape?  It turns out, if he had some stem cells to go with that face transplant, he could have just kept on wearing it. 

Surgical researchers did exactly that on four dogs and all 4 of the dogs tolerated the face transplants for over one year without immunosuppressive drugs after the first month.  – David

http://pagesfromserendipity.files.wordpress.com/2010/11/smiling-dog.jpg

Surgeons Develop Simultaneous Tissue and Stem Cell Transplant Technique

Released: 10/18/2011 11:00 AM EDT
Embargo expired: 10/27/2011 2:15 PM EDT
Source: American College of Surgeons (ACS)

New method shows promise in eliminating the need for long-term antirejection drugs, particularly for hand and face transplants

Newswise — SAN FRANCISCO: Surgical researchers at the University of Washington, Seattle, have pioneered a method using stem cells that may one day eliminate the need for antirejection drugs in transplants. Primary investigator David Mathes, MD, FACS, and his research fellow Jeff Chang, MD, MS, presented their findings today at the 2011 Clinical Congress of the American College Surgeons. Two groups of patients who might one day benefit from this early research breakthrough are hand and face transplant recipients. To date, survival of these transplants has depended on administering high-dose drugs to patients that suppress the immune system like those used in major organ transplants. However, these drugs are expensive and have a multitude of side effects, the researchers explained.

The surgeons performed simultaneous transplants of vascularized composite allografts—transplanted tissue with the blood vessels intact—and stem cells in four dogs followed by a short course of immune-suppressing drugs. All four dogs accepted the grafts without complications. After about a month, the researchers discontinued all immune system suppressing drugs. One dog rejected its stem cell transplant 10 weeks after the operation, but continued to tolerate the composite allograft for over one year without immunosuppression.

The other three dogs tolerated both stem cells and composite allografts for over one year. The investigators also performed vascularized composite allograft transplants without the stem cells on three other dogs. All three rejected the transplants after immune-suppressing drugs were stopped.

“If this technique works and proceeds into a clinical model, we would be able to transplant patients with either face or hands or even solid organs without the need for long-term immunosuppression drugs,” according to Dr. Chang. Physicians prescribe these drugs to people who have undergone hand and face transplants because organ transplant recipients, such as those receiving a liver or kidney, must take high-dose drugs to suppress the immune system and stave off organ rejection. Innovators of the hand and face transplants have followed this protocol to similarly prevent tissue rejection.

However, the side effects of these drugs have been widely reported. Kidney transplant recipients, for example, have a heightened risk of developing diabetes and hypertension. These drugs also raise the likelihood of infections and malignancy in all transplant recipients, Dr. Chang explained. Moveover, the American Society of Transplant Surgeons has estimated that immune-suppressing drugs can cost up to $25,000 a year per person.

While solid organ transplants are considered life-prolonging procedures in which the benefits outweigh the drug side effects, Dr. Chang noted that hand and face transplants do not fit this category. “Face and hand transplants are not life-saving procedures, so not subjecting these patients to the risks of immunosuppression would certainly be beneficial to them,” Dr. Chang said.

Although this research is still in an early phase, an important new finding the University of Washington study unveiled is the role that stem cells play in making the body tolerant of transplanted tissue, Dr. Chang said. “It’s interesting that you can modulate the immune system in such a way that you can transplant other cells into the recipient and the recipient becomes tolerant of them,” he said.

The study involved vascularized composite allograft transplants matched to the recipient’s tissue type. The next step is to attempt transplants in what Dr. Chang called a “mismatched” setting—where the donor and recipient tissue types do not necessarily match. “If we can get this to work in a mismatched setting it would be more clinically relevant,” Dr. Chang said.

Dr. Mathes and his collaborators at the Fred Hutchinson Cancer Research Center are attempting to develop this experimental model into a more clinical model for humans. The use of a canine model for this research is significant because large animals more closely resemble human anatomy and physiology with regard to composite allograft transplants, whereas “trying this method in small animals, such as laboratory mice, would be more difficult to translate into humans,” Dr. Chang explained.

Although the researchers embarked on developing this technique with hand and face transplants in mind, simultaneous mismatched tissue and stem cell transplantation may also hold promise for solid organ transplants. “If we extend this technique into solid organ transplantation, it would assist with a major problem; whether or not you need a complete match,” Dr. Chang said. “The other problem is supply and demand. If we can break the immunological barriers in such a way that would let us transplant a mismatched kidney, it would help greatly with the shortage of organs.”

David Mathes, MD, FACS, is the primary investigator for this project. Jeff Chang, MD, MS, is his research fellow. Both collaborated with Rainer Storb, MD, at the Fred Hutchinson Cancer Research Center in Seattle.

Surgeons Develop Simultaneous Tissue and Stem Cell Transplant Technique.

For those of you interested in the https://i2.wp.com/www.imodownload.com/imageupload/hcb_01.jpgbehind this, go here:

https://repairstemcell.wordpress.com/2011/10/27/silence-of-the-lambs-meets-stem-cells-the-hardcore-science/

INTESTINAL STEM CELLS RESPOND TO FOOD BY SUPERSIZING THE GUT

In STEM CELLS IN THE NEWS on October 27, 2011 at 6:24 pm

Request more treatment info.

INTESTINAL STEM CELLS RESPOND TO FOOD BY SUPERSIZING THE GUT

SO now we know that stem cells change your body all the time to deal with changes in your environment and what you eat.  Is it getting clearer? – David

Intestinal stem cells respond to food by supersizing the gut

BERKELEY —

A new study from University of California, Berkeley, researchers demonstrates that adult stem cells can reshape our organs in response to changes in the body and the environment, a finding that could have implications for diabetes and obesity…

Intestinal stem cells respond to food by supersizing the gut.

DIABETES CLINICAL TRIALS

  • FIRST USE OF CORD BLOOD TO ALTER COURSE OF TYPE 1 DIABETES, June 25, 2007 – (I’ll bet nobody heard of this one!)transfusion of stored, autologous (i.e. the person’s own), umbilical cord blood into a group of children newly diagnosed with type 1 diabetes appears to have reduced their disease severity, possibly re-setting the immune system and slowing the destruction of their insulin-producing cells, according to a report presented today at the American Diabetes Association’s 67th Annual Scientific Sessions. –http://parentsguidecordblood.org/content/media/m_pdf/ADA_T1D_PR-06-25-07.pdf(The ADA in 2007 knew stem cells can treat Diabetes type 1 in children!)
  • Diabetes type 1 stem cell clinical trial – Enrollment 11/2003-4/2008, follow-up until December 2008 – https://repairstemcell.wordpress.com/2009/09/14/type-1-diabetes-stem-cells-clinical-trial/
  • Why no diabetes clinical trial s in the US when mice were cured of diabetes type 1 in the 1990’s? –  Weissman, a professor of pathology and developmental biology at Stanford University, states: “Stem cells are rare, self-renewing, and can regenerate body tissues.” He repeatedly expressed frustration that while many of his discoveries seemed to hold remarkable potential for life-saving treatments, commercial or regulatory hurdles have prevented his scientific research from benefiting human beings. One example is, his mid-’90s research on type I diabetes, in which he demonstrated the ability to fully cure type I diabetes in mice using stem cells. Even though the experiments avoided political controversy by using adult/repair stem cells, which do not come from embryos, Weissman ran into a road block when pharmaceutical companies refused to sponsor clinical trials. The therapy went nowhere. “The pharmaceutical companies had put profit over principle, preferring to keep diabetes sufferers dependent on costly insulin than to cure them once and for all.” – https://repairstemcell.wordpress.com/2009/09/13/research-from-90s-cures-type-1-diabetes/

If you or a loved one is interested in receiving FREE information on currently available stem cell treatments for DIABETES or PERIPHERAL ARTERY DISEASE, please contact me at dsgrano@gmail.com or for other options, go to: CONTACT ME

HOPE FOR DIABETES SUFFERERS

In ALL ARTICLES on October 27, 2011 at 2:05 pm

THERE IS HOPE

I am continuously amazed at the wet blanket attitude that is projected by so many in light of significant stem cell breakthroughs.

First they say: “stem cell treatment has enabled patients with type 1 diabetes to go for as long as four years without insulin injections”

…pretty awesome huh?

Then they say: “the team warned the treatment may only work in those very recently diagnosed”

…oh, really…bummer.

Let’s just overlook that “recently diagnosed” actually means “recently developed symptoms” (I am fairly sure they don’t mean a 75 yr old grandmother who was “recently diagnosed” as having lived with diabetes for 55 years.) and as my friend the actuary likes to say: “Let’s just concentrate on the numbers.”

  • · Diabetes Prevalence – Total: 23.6 million children and adults — 8.0% of the population — have diabetes.  The total prevalence of diabetes increased 13.5% from 2005-2007.
  • · Diagnosed: 17.9 million people
  • · Undiagnosed: 5.7 million people (24%!)
  • · Pre-diabetes: 57 million people
  • · 1.6 million new cases of diabetes were diagnosed in people aged 20 years or older in 2007.

http://www.diabetes.org/diabetes-statistics.jsp

———————–

Ok, those are the numbers….So how SHOULD this article have been written?

How about…

World celebrates as new results prove diabetes pandemic can be stopped in it’s tracks with early detection!  Government to spend 10 million on improved early diabetes detection. (wait, where would they get the money…oh!) Money to be saved from not having to spend 100 million on late stage diabetes treatments.

Or….

5.7 million undiagnosed diabetes victims can now be saved from the trials of diabetes, amputation, blindness, kidney disease…etc with a single blood test.

Maybe you can come up with a different slant?

Point is; this is HUGE news!  Can we now cure every diabetic in the world?  No.  But we can potentially cure MILLIONS and this is a time for celebration for those people…and a time for optimism for the potential cures for others who are more advanced (as the science improves)…not a time for warnings of limitations.

But no, they stick to the glass is half empty position and say:
“It would be wrong to unnecessarily raise the hopes of people living with diabetes about a new treatment for the condition on the back of the evidence provided in this study.”

But you know what I think?

I think caution is good…but we are talking about people who are living with diabetes!  In my book, that makes them pretty damn tough already.  They are not little kittens and they don’t have to have their hopes “managed” or “spoon fed” to them.  In fact, raising their hopes may be EXACTLY what they need to survive through one more day of diabetes related pills and insulin, threats of blindness and amputation, reduction of lifespan, kidney and liver disease…etc. etc.

So celebrate the victories, embrace the hope and ALWAYS remember:

“If you lose hope, somehow you lose the vitality that keeps life moving, you lose that courage to be, that quality that helps you go on in spite of it all. And so today I still have a dream.” Martin Luther King, Jr.

And as far as false hope, there is no such thing. There is only hope or the absence of hope-nothing else. – Patti Davis

 

hope-1

“There is only hope or the absence of hope-nothing else.

DAMN STRAIGHT!

FAKE AND FRAUDULENT SCIENCE

In DISEASE INFO on October 27, 2011 at 2:32 am

FAKE AND FRAUDULENT SCIENCE

  • Scientific empirical data is subject to misinformation and corruption as much as what some refer to as the “soccer mom hysteria.”
    For example:  Dr Thorsen’s data on the correlation between MMR vaccines and Autism is corrupt and dependent on elements outside the study both ignored and cherry picked around:

    “Thorsen was a leading member of a Danish research group that wrote several key studies supporting CDC’s claims that the MMR vaccine and mercury-laden vaccines were safe for children. Thorsen’s 2003 Danish study reported a 20-fold increase in autism in Denmark after that country banned mercury based preservatives in its vaccines. His study concluded that mercury could therefore not be the culprit behind the autism epidemic.

    His study has long been criticized as fraudulent since it failed to disclose that the increase was an artifact of new mandates requiring, for the first time, that autism cases be reported on the national registry. This new law and the opening of a clinic dedicated to autism treatment in Copenhagen accounted for the sudden rise in reported cases rather than, as Thorsen seemed to suggest, the removal of mercury from vaccines. Despite this obvious chicanery, CDC has long touted the study as the principal proof that mercury-laced vaccines are safe for infants and young children. Mainstream media, particularly the New York Times, has relied on this study as the basis for its public assurances that it is safe to inject young children with mercury — a potent neurotoxin — at concentrations hundreds of times over the U.S. safety limits.

    Thorsen, who was a psychiatrist and not a research scientist or toxicologist, parlayed that study into a long-term relationship with CDC. He built a research empire called the North Atlantic Epidemiology Alliances (NANEA) that advertised its close association with the CDC autism team, a relationship that had the agency paying Thorsen and his research staff millions of dollars to churn out research papers, many of them assuring the public on the issue of vaccine safety.

    The discovery of Thorsen’s fraud came as the result of an investigation by Aarhus University and CDC which discovered that Thorsen had falsified documents and, in violation of university rules, was accepting salaries from both the Danish university and Emory University in Atlanta — near CDC headquarters — where he led research efforts to defend the role of vaccines in causing autism and other brain disorders. Thorsen’s center has received $14.6 million from CDC since 2002.

    Thorsen’s partner Kreesten Madsen recently came under fierce criticism after damning e-mails surfaced showing Madsen in cahoots with CDC officials intent on fraudulently cherry picking facts to prove vaccine safety.

    Leading independent scientists have accused CDC of concealing the clear link between the dramatic increases in mercury-laced child vaccinations beginning in 1989 and the epidemic of autism, neurological disorders and other illnesses affecting every generation of American children since. Questions about Thorsens’s scientific integrity may finally force CDC to rethink the vaccine protocols since most of the other key pro vaccine studies cited by CDC rely on the findings of Thorsen’s research group. These include oft referenced research articles published by the Journal of the American Medical Association, the American Journal of Preventive Medicine, the American Academy of Pediatrics, the New England Journal of Medicine and others. The validity of all these studies is now in question.”

    via https://repairstemcell.wordpress.com/2010/03/15/cdc-vaccine-cover-up-mercury-actually-does-cause-autism/

mercury toxic element,Who Discovered Mercury,mercury element,toxic,tannoy f4 custom,poisoning symptoms,interesting facts about mercury,facts on the planet,outboard motors,how many moons does,how far is from the sun, insurance complaints,lithgow mercury,outboard motor parts,passenger vehicles e bay motors,manhattan mercury,who discovered the planet,pottstown mercury newspaper,mercury gemini mind games,mercury engine oil,what color is mercury,pictures of mercury,mercury grand  marquie clubs,mercury symbol,san jose mercury newspaper

 

  • PFIZER, CELEBREX, BEXTRA + VIOXX CLINICAL TRIAL RESULTS WERE FAKE- FRAUD
    February 18, 2010 at 1:55 pm “It’s being called the largest research fraud in medical history. Dr. Scott Reuben, a former member of Pfizer’s speakers’ bureau, has agreed to plead guilty to faking dozens of research studies that were published in medical journals. Now being reported across the mainstream media is the fact that Dr. Reuben accepted a $75,000 grant from Pfizer to study Celebrex in 2005. His research, which was published in a medical journal, has since been quoted by hundreds of other doctors and researchers as “proof” that Celebrex helped reduce pain during post-surgical recovery. There’s only one problem with all this: No patients were ever enrolled in the study!” https://repairstemcell.wordpress.com/2010/02/18/pfizer-celebrex-bextra-vioxx-clinical-trial-results-were-fake-fraud/


    repairstemcell.wordpress.com

    ‎”It’s being called the largest research fraud in medical history. Dr. Scott Reu…

 

  • and need I mention the Embyonic hoax perpetrated on the US populace for a decade?

    The pure and impartial and just eye of the scientist is just as susceptible to partiality as any other if not more so because they think thy can get away with it.

    The Placebo Defecthttp://naturalnews.com/030209_placebo_medical_fraud.html

    “This is the conclusion from researchers at the University of California who published their findings in the October issue of the Annals of Internal Medicine. They reviewed 167 placebo-controlled trials published in peer-reviewed medical journals in 2008 and 2009 and found that 92 percent of those trials never even described the ingredients of their placebo pills.”

    Empirical science is not a hat you take off when it is convenient. Everything has an effect and if test tubes are not sterile and compounds are contaminated and trials are screwed up then they can not be considered valid. 92%. Nuff said.

https://i2.wp.com/no92.com/assets/images/autogen/a_nO92_logo.gif

%d bloggers like this: